Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Expands By 79.1%

Autolus Therapeutics plc (NASDAQ:AUTL) saw a large growth in short interest in June. As of June 15th, there was short interest totalling 6,430,000 shares, a growth of 79.1% from the May 31st total of 3,590,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is currently 4.1 days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC purchased a new position in Autolus Therapeutics in the 1st quarter worth approximately $78,765,000. Price T Rowe Associates Inc. MD increased its stake in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. Affinity Asset Advisors LLC increased its position in shares of Autolus Therapeutics by 117.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after purchasing an additional 1,824,592 shares during the last quarter. Perpetual Ltd increased its position in shares of Autolus Therapeutics by 8.2% during the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after purchasing an additional 169,784 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in Autolus Therapeutics in the 4th quarter valued at $11,793,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Trading Up 4.5 %

Shares of Autolus Therapeutics stock traded up $0.15 during trading hours on Friday, reaching $3.48. 2,450,789 shares of the stock traded hands, compared to its average volume of 1,464,718. The company has a 50 day moving average price of $4.03 and a 200 day moving average price of $5.32. Autolus Therapeutics has a one year low of $2.01 and a one year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). The firm had revenue of $10.09 million during the quarter, compared to analysts’ expectations of $50.00 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Analysts predict that Autolus Therapeutics will post -0.78 EPS for the current year.

Analyst Ratings Changes

AUTL has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, June 17th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. Finally, Truist Financial boosted their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.